PROGRAMME Poster Presentations
01. Helicobacter - Round 01
Chair: Peter Malfertheiner, Germany & Mashiko Setshedi, South Africa
P 01.001. - Anti-parietal cell antibody levels and gastric atrophy in a South and Southeast Asian general population
Mitsushige Sugimoto, Yufu, Japan
P 01.002. - Korean registry on the current management of Helicobacter pylori (K-Hp-Reg): Interim analysis of adherence to the revised evidence-based guidelines for first-line treatment
Hyo-Joon Yang, Seoul, Korea, Republic of
P 01.003. - To fail or not to fail - an update from the UK on the treatment outcomes of 462 patients from the European Registry on H. pylori management (Hp-EuReg)
Jan Bornschein, Oxford, United Kingdom
P 01.004. - Comparative analysis of 7-day fexuprazan-based and 14-day rabeprazole-based triple therapies for Helicobacter pylori eradication
Sung Chul Park, Chuncheon, Korea, Republic of
P 01.005. - Empirical eradication therapy for Helicobacter pylori infection in second and subsequent treatment lines: experience from 500 cases of the Brazilian registry on H. pylori management (Hp-BrazilReg)
Luiz Coelho, Belo Horizonte, Brazil
P 01.006. - Investigation of the Association Between Gastric Intestinal Metaplasia and Map-Like Redness in the Mucosa After Helicobacter pylori Eradication Therapy
Osamu Matsunari, Oita, Japan
P 01.007. - Vonoprazan is highly effective and safe as an adjuvant in different regimes in first- and rescue-line therapies for H. pylori infection in Brazil
Luiz Coelho, Belo Horizonte, Brazil
P 01.008. - Second- and third-line therapies for Helicobacter pylori eradication in Slovenia: Data from 2013-2024 of the European Registry on H. pylori Management
Bojan Tepes, Rogaska Slatina, Slovenia
P 01.009. - A randomized, double-blind, active-controlled, multicenter study to evaluate the safety and efficacy of tegoprazan-based standard triple therapy for Helicobacter pylori eradication
Jae Gyu Kim, Seoul, Korea, Republic of
P 01.010. - Abstract Withdrawn
P 01.011. - Eurohelican - Accelerating gastric cancer reduction through Helicobacter pylori eradication - First screen and treat application study in Europe
Bojan Tepes, Rogaska Slatina, Slovenia
01. Helicobacter - Round 02
Chair: Laimas Jonaitis, Lithuania & Yaron Niv, Israel
P 01.023. - Abstract Withdrawn
P 01.024. - Abstract Withdrawn
P 01.025. - The significance of Helicobacter pylori gastritis found during upper endoscopy performed for the diagnosis of celiac disease in pediatric patients
Michal Kori, REHOVOT, Israel
P 01.026. - Establishing Epidemiologic Cut-Off Values for Helicobacter pylori in Korea: A Model-Based Analysis of Antibiotic Resistance Patterns
Hwoon-Yong Jung, Seoul, Korea, Republic of
P 01.027. - Outcome of Helicobacter pylori third-line eradication therapy and consideration of unsuccessful cases
Kumiko Ueda, Tokyo, Japan
P 01.028. - Local cytoprotection with alpha-glutamyl-tryptophan in the treatment of chronic atrophic gastritis, associated with Helicobacter pylori: results of histological and immunohistochemical examination
Natalia Baryshnikova, St-Petersburg, Russian Federation
P 01.029. - Development of a gyrase A gene-based, universal qPCR assay for H. pylori strains
Zhongming Ge, Cambridge, United States
P 01.030. - Untargeted metabolomic profiling as a new tool to identify systemic signatures of Helicobacter pylori infection in a guinea pig model
Weronika Gonciarz, Lódz, Poland
P 01.031. - Children characteristics and treatment eradication rate of Helicobacter pylori (H. pylori) infection: Results from the French speaking Groupe of Pediatric Gastro-Hepatology and Nutrition on H. pylori registry (GFHGNP-H. pylori registry)
Nicolas Kalach, Lille, France
P 01.032. - The effectiveness and adverse events of first- and second-line therapy in the treatment of helicobacter pylori - data from a greek hospital
Athanasios Kontos, Athens, Greece
P 01.033. - Susceptibility-guided therapy versus Empiric Therapy for H. pylori Treatment Failures: A Nationwide Longitudinal Study (SGT-HP Trial)
Ratha-korn Vilaichone, Pathumthani, Thailand
01. Helicobacter - Round 03
Chair: Jan Bornschein, United Kingdom & Alexander Link, Germany
P 01.045. - Impact of Helicobacter pylori Infection and serum pepsinogen on skeletal muscle mass
Daisuke Chinda, Hirosaki, Japan
P 01.046. - Prevalence of Primary Clarithromycin, Metronidazole and Levofloxacin Resistance in Patients Infected with Helicobacter pylori in Europe: a review of the last four decades
Olga P. Nyssen, Madrid, Spain
P 01.047. - Literature-based Helicobacter pylori resistance data integrated into the European Registry on H. pylori management (Hp-EuReg): limited usefulness for predicting first-line empirical treatment effectiveness
Olga P. Nyssen, Madrid, Spain
P 01.048. - Effectiveness of first-line empirical Helicobacter pylori treatment outside Europe: results of 10,000 cases from the World-Wide Registry on H. pylori Management (WorldHpReg)
Olga P. Nyssen, Madrid, Spain
P 01.049. - Prescription of first-line empirical treatments for Helicobacter pylori infection outside Europe: results of 10,000 cases from the World-Wide Registry on H. pylori Management (WorldHpReg)
Olga P. Nyssen, Madrid, Spain
P 01.050. - Impact of drug dosages on the effectiveness of first-line bismuth quadruple therapy: results from 11,000 patients from the European Registry on Helicobacter pylori management (Hp-EuReg)
Pablo Parra, Madrid, Spain
P 01.051. - Prescriptions and effectiveness of alternative and infrequent Helicobacter pylori eradication regimens: insights from the European Registry on H. pylori Management (Hp-EuReg)
Olga Nyssen, Madrid, Spain
P 01.052. - The metachonous gastric cancer risk according to the Helicobacter pylori infection status and age group in elderly early gastric cancer who underwent endoscopic submucosal dissection
Young-Il Kim, Goyang, Korea, Republic of
P 01.053. - Droplet Digital PCR-based Detection of Clarithromycin Resistance on Rapid Urease Test Samples Predicts Helicobacter pylori Eradication Success: A New Zealand Cohort Study
Stephen Inns, Wellington, New Zealand
P 01.054. - Clinical impact of Helicobacter pylori treatment on gastrointestinal bleeding after percutaneous coronary intervention in patients with acute myocardial infarction - A nationwide population-based cohort study
Beom Jin Kim, Seoul, Korea, Republic of
P 01.055. - Mycobacterium bovis BCG reverses deleterious effects of H. pylori components towards gastric barrier cells in vitro
Weronika Gonciarz, Lódz, Poland
01. Helicobacter - Round 04
Chair: Yoshio Yamaoka, Japan & Vladimir Milivojevic, Belgrade, Serbia
P 01.068. - Evaluation of Helicobacter pylori Infection and Current Antibiotic Resistance Patterns in Dyspeptic Patients from Turkey: Preliminary Findings
Reyhan Caliskan, Samsun, Turkey
P 01.069. - Helicobacter pylori Infection and Histopathological Analysis of Gastric Mucosal Changes in Patients with Dyspeptic Symptoms - A Regional Evaluation
Reyhan Caliskan, Samsun, Turkey
P 01.070. - Helicobacter pylori eradication promotes a systemic anti-inflammatory shift in duodenal ulcer patients compared to those with gastritis
Fabrício Freire de Melo, Universidade Federal da Bahia (UFBA), in Vitória da Conquista, Brazil
P 01.071. - Efficacy comparison of 7- and 14-day P-CAB-based bismuth-containing quadruple regimen with PPI-based bismuth-containing quadruple regimen for Helicobacter pylori infection: an open-label, multicenter, randomized controlled trial
Hyun Lim, Anyang-si, Korea, Republic of
P 01.072. - Abstract Withdrawn
P 01.073. - Abstract Withdrawn
P 01.074. - Diagnostic features of autoimmune gastritis with differentHelicobacter pyloriinfection status
Maria Livzan, Omsk, Russian Federation
P 01.075. - Diagnostic accuracy of PCR-based Helicobacter pylori testing compared to conventional methods
Alexander Link, Magdeburg, Germany
P 01.076. - Abstract Withdrawn
P 01.077. - microbiological quality of bottled water and presence of Helicobacter pylori DNA in Bogotá (Colombia)
Fidson Vesga, Bogotá, Colombia
P 01.078. - Screening for Helicobacter pylori, gastric atrophy and autoimmune gastritis in a single centre in Bulgaria
Mila Kovacheva-Slavova, Sofia, Bulgaria
P 01.079. - Therapeutic outcomes of tailored eradication therapy for Helicobacter pylori according to 23S rRNA point mutation types in a Korean population
Yoo Min Han, Seoul, Korea, Republic of
01. Helicobacter - Round 05
Chair: Arnoldo Riquelme, Chile & Gianluca Quaranta, Italy
P 01.092. - The origin and pathogenicity of Helicobacter pylori strains in Estonia
Kaisa Roots, Tallinn, Estonia
P 01.093. - Comparison of two different PCR-based methods for the detection of Helicobacter pylori and its susceptibility to clarithromycin in complicated peptic ulcer cases
Gábor Lotz, Budapest, Hungary
P 01.094. - Abstract Withdrawn
P 01.095. - Features of the appointment of diagnostic tests for Helicobacter pylori by doctors of various specialties
Rashad Hasanov, Baku, Azerbaijan
P 01.096. - Economic analysis of susceptibility guided therapy compared with empirical therapy for Helicobacter pylori eradication
Joon Sung Kim, Incheon, Korea, Republic of
P 01.097. - Gastric IL-17A, IL-23, and IL-10 expression corelated with CagA, OipA, and BabA2 of Helicobacter pylori in patients with clinicopathological outcomes
Theeraya Simawaranon Bartpho, Nakhonratchasima, Thailand
P 01.098. - Real-world indications and eradication rates of first-line H. pylori therapies in germany: data from the european registry on H. pylori management (Hp-EuReg) with a focus on gastric cancer prevention
Marino Venerito, Magdeburg, Germany
P 01.099. - The role of vitamin C in the Helicobacter pyloriDormant State
Mara Di Giulio, Chieti, Italy
P 01.100. - The prevalence of Helicobacter spp. infection in current Japanese cholecystic bile
Yoshihasa Fukuda, Fukuoka, Japan
P 01.101. - Abstract Withdrawn
P 01.102. - The structural effects of the TLR4 receptor variant rs4986790 on the genetic predisposition to Helicobacter pylori infection.
Monica Barbosa, Goiania, Brazil
P 01.103. - Virulent H. pylori drives immune evasion and dna repair impairment in her2-positive N87 gastric cancer cell line
Valli De Re, Aviano, Italy
01. Helicobacter - Round 06
Chair: Danute Razuka-Ebela, Latvia & Franco Bazzoli, Italy
P 01.012. - Abstract Withdrawn
P 01.013. - Duodenogastric reflux and infectious gastritis
Adriana Barrios, Quetzaltenango, Guatemala
P 01.014. - Abstract Withdrawn
P 01.015. - Evaluation of a quintuple, 10-day bismuth-enhanced concomitant, therapy as a first-line regimen for Helicobacter pylori eradication: a prospective multicenter pilot study.
Christos Liatsos, Athens, Greece
P 01.016. - Comparison of 4 stool antigen tests for the detection of Helicobacter pylori
Alexe Momal, Godinne, Belgium
P 01.017. - The prevalence of detection of antibodies to CagA virulence factor of H.pylori in patients with a positive result for 13C- urease breath test in Moscow.
Dmitry Bordin, Moscow, Russian Federation
P 01.018. - Helicobacter pyloriinfection and gastric atrophic change in drug related small bowel bleeding
Na Rae Lim, Suwon, Korea, Republic of
P 01.019. - Trends in the prescription of eradication treatments and their effectiveness in naïve patients over 12 years (2013-2024) in Europe: data from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P 01.020. - Comparison of tailored therapy and concomitant therapy: focusing on clinical efficacy and cost-effectiveness
Moon Kyung Joo, Seoul, Korea, Republic of
P 01.021. - Empirical second-line treatments in Europe: data from 9,000 cases from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Pablo Parra, Madrid, Spain
P 01.022. - Effectiveness and safety of single-capsule bismuth quadruple therapy in 12,500 patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
01. Helicobacter - Round 07
Chair: Varocha Mahachai, Thailand & Theodore Rokkas, Greece
P 01.034. - Xenophagy found in Human and MouseHelicobacter suisinfected Gastric Parietal Cell is closely Related to Mitophagy
Masahiko Nakamura, Isehara, Japan
P 01.035. - Accurate Mucosal Sampling Site for Diagnosis of Helicobacter pylori Infection with Rapid Urease Test: A Prospective Cohort Study
Yuri Kim, Daegu, Korea, Republic of
P 01.036. - Efficacy of 10-Day Bismuth-Based Quadruple Therapy for H. pylori in a European Screening Pilot: Interim Results of the Irish Experience
Charlene Deane, Dublin, Ireland
P 01.037. - Factors associated with the lack of follow-up in Helicobacter pylori eradication treatment: results from the European Registry on H. pylori management (Hp-EuReg)
Pablo Parra, Madrid, Spain
P 01.038. - Population-Based Screening for Helicobacter Pylori in Western Europe: Interim Results of the Irish Experience
Charlene Deane, Dublin, Ireland
P 01.039. - The influence of Helicobacter pylori bacteria on the functional activity of phagocytic cells with gastrointestinal tract pathology
Oksana Kolenchukova, Krasnoyarsk, Russian Federation
P 01.040. - Targeted Versus Population-Based Screening for Helicobacter pylori: Interim Results of the Irish Experience
Charlene Deane, Dublin, Ireland
P 01.041. - Comparison of eradication rate of Helicobacter pylori between hemodialysis and non-hemodialysis patients
Moon Kyung Joo, Seoul, Korea, Republic of
P 01.042. - 7-Day vs. 14-Day Bismuth Quadruple Therapy as Second-line Treatment for Helicobacter pylori: Results from the K-CREATE Study
Byung-Wook Kim, Incheon, Korea, Republic of
P 01.043. - Helicobacter pylorieradication prescriptions in Primary Care: insights from over 200,000 patients in a national real-world cohort.
Olga P. Nyssen, Madrid, Spain
P 01.044. - Long-term effect of macrolide consumption on Helicobacter pylori eradication treatments: data from the European Registry on H. pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
01. Helicobacter - Round 08
Chair: Luiz Coelho, Brazil & Leonardo Henry Eusebio, Italy
P 01.056. - Identification of genes related to pyroptosis in Helicobacter pylori infection based on bioinformatics analysis
Kexing Dai, Chongqing, China
P 01.057. - Proteomic analysis and target gene identification of exosomes derived from Helicobacter pylori-infected gastric epithelial cell lines
Dong Chan Joo, Busan, Korea, Republic of
P 01.058. - Diagnosis of Helicobacter pylori infection in patients with dyspepsia: results of a survey of family physicians in Vinnytsia region, Ukraine
Dmytro Palii, Vinnytsya, Ukraine
P 01.059. - Prescription of eradication treatments according to current recommendation: trends prescribing by family doctors in Vinnytsia region, Ukraine
Dmytro Palii, Vinnytsya, Ukraine
P 01.060. - Association betweenHelicobacter pyloriinfection and socioeconomic development level in northeastern Romania
Elena Popovici, Bacau, Romania
P 01.061. - Prevalence of H.pylori infection in Married Couples in Moscow
Margarita Chebotareva, Moscow, Russian Federation
P 01.062. - Morphological diversity of Helicobacter pylori in human saliva observed by correlative light and electron microscope
Mi-Jin Jee, Seoul, Korea, Republic of
P 01.063. - Evaluation of three cases of idiopathic gastric antral ulcer
koji nakamichi, Fukuoka, Japan
P 01.064. - Endoscopic Predictors of Iron Deficiency in Helicobacter pylori Gastritis: A Kyoto Classification-Based Study
Hyun Tak Lee, Seongnam-si, Gyeonggi-do, Korea, Republic of
P 01.065. - Tailored treatment for H. pylori infection based on the result of a molecular diagnosis kit for detecting H. pylori using intragastric fluid
Mototsugu Kato, Sapporo, Japan
P 01.066. - Antibiotic resistance and heteroresistance of Helicobacter pylori: the importance of molecular testing, lessons from Serbia
Vladimir Milivojevic, Belgrade, Serbia
P 01.067. - CYP2C19 genetic polymorphism and its impact on Helicobacter pylori eradication: A Serbian study experience
Vladimir Milivojevic, Belgrade, Serbia
01. Helicobacter - Round 09
Chair: Christian Schulz, Germany & Stella Smith, Nigeria
P 01.080. - Gastric microbiota of Helicobacter pylori-positive and Helicobacter pylori-negative patients
Natalia Baryshnikova, St-Petersburg, Russian Federation
P 01.081. - cagA c-terminal variants in helicobacter pylori differentiate duodenal ulcer and gastric carcinoma
Sung Soo Kim, Uijongbu, Korea, Republic of
P 01.082. - Effectiveness of repeated use of amoxicillin-clarithromycin triple therapy and bismuth quadruple therapy after prior failure: preliminary results from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Olga Nyssen, Madrid, Spain
P 01.083. - Characterization of the zinc-metalloprotease activity ofHelicobacter pyloriouter membrane protein B (HomB) and its possible role in driving inflammatory responses
Sergen Akaysoy, Giessen, Germany
P 01.084. - Positive association between anti-Helicobacter pylori IgG antibody titers and atrophic gastritis in a Latvian cohort
Joo Hyun Lim, Seoul, Korea, Republic of
P 01.085. - Correlation between Helicobacter pylori assay and UBT results in a population-based screening program, as based on interim results.
Ana Moore McKiernan, Dublin, Ireland
P 01.086. - Risk Factors influencing Seropositivity in a general population, the Irish Experience
Ana Moore McKiernan, Dublin, Ireland
P 01.087. - Clinical evaluation of a 14day modified bismuth quadruple therapy for the eradication of H. pylori in a high clarithromycin and metronidazole resistance area
Sotirios Georgopoulos, Athens, Greece
P 01.088. - Complicated Clinical Course of Ischemic Heart Disease (IHD) Patients with Concurrent Helicobacter pylori Infection During COVID-19: Based on Our Clinical Data
Mimoza Kankia, Tbilisi, Georgia
P 01.089. - Morphologic sighs of primary and secondary autoimmune gastritis
Sergey Khomeriki, Moscow, Russian Federation
P 01.090. - News on dyspepsia management: is routine biopsy mapping warranted in H. pylori-negative patients?
Giulia Fiorini, Bologna, Italy
P 01.091. - Accuracy of a new innovative column-free miniaturized gas-mass spectrometer (GMS) compared to a classic GMS to diagnose and monitoring Helicobacter pylori infection: a prospective single blind study
Giulia Fiorini, Bologna, Italy
01. Helicobacter - Round 10
Chair: José Machado, Portugal & Andrea Severino, Italy
P 01.104. - Prevalence of oipA and babA2 genes of Helicobacter pylori and their clinical correlations in patients from the state of Goiás, Brazil.
Monica Barbosa, Goiania, Brazil
P 01.105. - Molecular profile ofHelicobacter pyloriin patients from Central Brazil and its clinical implications.
Monica Barbosa, Goiania, Brazil
P 01.106. - Effectiveness of salivary antigen and urea breath test for diagnosing Helicobacter pylori in patients after subtotal gastrectomy Billroth II
Ayoung Lee, Ansan-si, Korea, Republic of
P 01.107. - The relationship between Helicobacter pylori and intestinal metaplasia in ulcer and non-ulcer dyspepsia: An endoscopic and histopathological evaluation
Esra Taş, Samsun, Turkey
P 01.108. - Impact of comorbidities and Helicobacter pylori infection status on survival of patients with gastric cancer in Brazil
Monica Barbosa, Goiania, Brazil
P 01.109. - Repeated H. pylori Eradication Therapy Prescribing in Irish Primary Care: A 10-Year Review
Marta Dobrić, Dublin, Ireland
P 01.110. - Predicting Helicobacter pylori reinfection after successful initial eradication with first-line quadruple therapies in a South-European country
Elisa Gravito-Soares, Coimbra, Portugal
P 01.111. - Clarithromycin exposure modulates efflux gene expression in H. pylori in a strain specific manner
Stephen Molloy, Dublin24, Ireland
P 01.112. - First-line treatment of Helicobacter pylori infection in clinical practice in Italy: Data from the Italian Registry on Helicobacter pylori treatment (Hp-ItaReg)
Rocco Zagari, Bologna, Italy
P 01.113. - Helicobacter Pylori Infection associated with Non-Thyroidal Ilness syndrome in children with congenital Hypothyroidism
Dulciene Queiroz, Universidade Federal de Minas Gerais (UFMG), in Belo Horizonte, Brazil
P 01.114. - Preliminary Insights from a National Survey on Current Clinical Practices in the Diagnosis and Management of Helicobacter pylori Infection in Ireland.
Conor Costigan, Dublin, Ireland
P 01.115. - Proinflammatory Effects of Helicobacter pylori Outer Membrane Vesicles (OMVs) on Gastric Cells via TLR2/NF-κB Signaling
Manuel Valenzuela Valderrama, Santiago, Chile
02. Microbiota - Round 01
Chair: Lucrezia Laterza, Italy & Giovanni Marasco, Italy
P 02.001. - Two cases of newly developed ulcerative colitis following clinical and endoscopical remission of acute bacterial colitis
Jongkyu Kim, seoul, Korea, Republic of
P 02.002. - Clinical and colonoscopic features of proctitis in Chlamydia trachomatis positive patients mimicking ulcerative colitis over the past 6 years
Jongkyu Kim, seoul, Korea, Republic of
P 02.003. - Differences in gut microbiota based on gastric acid secretion: effects of Helicobacter pylori-induced gastric mucosal atrophy, proton pump inhibitor use, and total gastrectomy
Chikara Iino, Hirosaki city, Japan
P 02.004. - Abstract Withdrawn
P 02.005. - Small Intestinal Bacterial Overgrowth (SIBO) as an Independent Indicator of Liver Stress in Chronic Hepatitis Patients
Rashad Hasanov, Baku, Azerbaijan
P 02.006. - Interplay Between Small Intestinal Bacterial Overgrowth, Liver Fibrosis, and Viral Load in Chronic Hepatitis
Rashad Hasanov, Baku, Azerbaijan
P 02.007. - Imaging and microorganism analyses of the effects of oral Bifidobacterium breve intake on facial skin in females: A randomized, double-blind, placebo-controlled study
Yuriko Nishikawa, Tokyo, Japan
P 02.008. - Gut feeling: exploring the impact of Microbiota on mental health through Psychobiotics - a systematic review
Alexandra Oros, Cluj-Napoca, Romania
P 02.009. - Management and Outcomes of Immune Checkpoint Inhibitor-Associated Colitis and Diarrhea: A Systematic Review and Meta-Analysis
Chiara Esposito, Roma, Italy
P 02.010. - Prevalence and characteristics of gastrointestinal symptoms in patients with recurrent urinary tract infections from enteric pathobionts.
Enrico Capuano, Rome, Italy
P 02.011. - Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile infection: a long standing experience of a referral centre
Andrea Severino, Rome, Italy
02. Microbiota - Round 02
Chair: Georgina Hold, Australia & Serena Porcari, Italy
P 02.012. - Efficacy and safety of pyridostigmine for severe chronic constipation refractory to first line treatments
Andrea Severino, Rome, Italy
P 02.013. - Clinical outcomes of cancer patients with gastrointestinal immune-related adverse events during therapy with immune checkpoint inhibitors: experience of a tertiary care outpatient gastroenterology clinic
Franziska Deutschbein, Roma, Italy
P 02.014. - Types of intestinal microbiome changes in multiple sclerosis and their relationship with disease severity
Natalia Baryshnikova, St-Petersburg, Russian Federation
P 02.015. - Feasibility of gastric microbiome profiling via gastric mucosal swab: comparison with biopsy
Hyunsoo Chung, Seoul, Korea, Republic of
P 02.016. - Gut microbiota modulation as a novel therapeutic approach for immune-checkpoint inhibitors-related diarrhea and colitis
Franziska Deutschbein, Roma, Italy
P 02.017. - Time‑Resolved Plasma and Stool Metabolomic Responses to Fecal Microbiota Transplantation
Jung Hwan Lee, Incheon, Korea, Republic of
P 02.018. - The influence of cytostatics on gut microbiota of CRC patients studiedin vitro
Natalia Baryshnikova, St-Petersburg, Russian Federation
P 02.019. - Culturable bacterial species in stomach biopsy samples from high-risk gastric cancer areas of Colombia in a longitudinal (20- and 26-year) study.
Zeli Shen, Cambridge, United States
P 02.020. - Abstract Withdrawn
P 02.021. - Proteus mirabilis urease: new roles in gut-brain communication and Parkinson’s Disease pathogenesis
Eduarda Nachtigall, Porto Algre, Brazil
P 02.022. - Investigating the role of gut microbiota in glioblastoma development
Sarah Lavielle, Bordeaux, France
P 02.023. - Taxonomic profiling of gut microbiota in liver transplant candidates using a Galaxy based metagenomic workflow
Rosa Ragozzino, Roma, Italy
02. Cancer - Round 01
Chair: Johannes Björk, Netherlands & Ari Ristimäki, Finland
P 03.001. - Risk factors for lateral margin positivity following endoscopic submucosal dissection in patients with early gastric cancer.
Sunhyung Kang, Daejeon, Korea, Republic of
P 03.002. - Abstract Withdrawn
P 03.003. - Role of Helicobacter pylori infection in immunotherapy response in gastric and oeso-gastric cancer (oeso-gastric junction and lower oesophagus)
Elina Lam, Bruxelles, Belgium
P 03.004. - Abstract Withdrawn
P 03.005. - The role of YAP/TAZ signal pathway in Helicobacter induced gastric carcinongenesis
Yong Chan Lee, Seoul, Korea, Republic of
P 03.006. - Usefulness of endoscopic submucosal dissection for the indefinite biopsy pathology
Jeong Seop Moon, Seoul, Korea, Republic of
P 03.007. - Abstract Withdrawn
P 03.008. - Treatment outcomes and prognosis of endoscopic submucosal dissection for early gastric cancer in elderly patients: a single-center, retrospective study
Yukako Yagi, Kasuga-shi, Fukuoka, Japan
P 03.009. - Prognostic Insights: Identifying Critical Factors in Early-Onset Gastric Cancer Over a Decade - The EOGC-Prognosis Trial
Ratha-korn Vilaichone, Pathumthani, Thailand
P 03.010. - Unraveling the mystery of young gastric cancer patients in asean: a large longitudinal study from low prevalence area of gastric cancer (young-gc-asean trial)
Ratha-korn Vilaichone, Pathumthani, Thailand
P 03.011. - Abstract Withdrawn
P 03.012. - Disparities in H. pylori-Related Gastric Cancer Awareness and Management Among Azerbaijani Physicians: A National Cross-Sectional Survey
Rashad Hasanov, Baku, Azerbaijan
P 03.013. - Bridging the Gap Between Gastric Cancer Burden and Screening Readiness in Azerbaijan: Epidemiological Context and Physician Survey Insights
Rashad Hasanov, Baku, Azerbaijan
P 03.014. - Changes in body composition and clinical outcomes following endoscopic submucosal dissection versus total gastrectomy in patients with proximal early gastric cancer
Sung Kwan Shin, Seoul, Korea, Republic of
02. Cancer - Round 02
Chair: Ceu Figueiredo, Portugal & Lisa Derosa, France
P 03.015. - Suicide mortality by clinical stage in patients with gastric cancer: A nationwide population-based cohort study
Bokyung Kim, Seoul, Korea, Republic of
P 03.016. - Doxorubicin loaded polylactide nanoparticles functionalized histamine promote apoptosis of human gastric cancer cells AGS
Patrycja Jaroniek, Lodz, Poland
P 03.017. - An artificial intelligence system for detecting and diagnosing esophageal squamous cell carcinoma and precancerous lesions using endoscopic images and videos
Yoonhee Lee, Seoul, Korea, Republic of
P 03.018. - Long term outcomes and recurrence of gastric neuroendocrine tumors : a single center study
Yu Kyung Cho, Seoul, Korea, Republic of
P 03.019. - clinicopathologic significance of ezrin expression in gastric carcinoma and its association with helicobacter infection
Sung Soo Kim, Uijongbu, Korea, Republic of
P 03.020. - Vaginal microbiome in patients with endometrial cancer
Natalia Baryshnikova, St-Petersburg, Russian Federation
P 03.021. - Test and scope to identify gastric precancerous lesions in 2171 dyspeptic patients.
Giulia Fiorini, Bologna, Italy
P 03.022. - Expression of interleukin-17 receptors, IL-17RA, IL-17RC, and IL-17RE in gastric cancer and its potential in carcinogenesis associated with Helicobacter pylori infection
Lucas Rasmussen, Ourinhos, Brazil
P 03.023. - Impact of Helicobacter pylori infection on IL-17RB expression in gastritis and gastric cancer
Lucas Rasmussen, Ourinhos, Brazil
P 03.024. - Physicians' attitudes towards the possible introduction of stomach cancer screening
Rashad Hasanov, Baku, Azerbaijan
P 03.025. - Hydrogen sulfide prevention of Helicobacter pylori-induced gastric cancer
Gracjana Krzysiek-Maczka, Krakow, Poland
P 03.026. - Positive fecal immunochemical test and dsc co-testing for gastric cancer risk stratification
Valli De Re, Aviano, Italy
P 03.027. - "'Watch and Wait” strategy in rectal cancer: Clinical evidence and oncological benefits
Monica Barbosa, Goiania, Brazil